ProQR Therapeutics (PRQR) FCF Margin (2021 - 2022)
ProQR Therapeutics recorded quarterly FCF Margin of 2154.72% in Q4 2022, down 16.02% quarter-over-quarter from 1857.25% in Q3 2022, and down 383255.0% year-over-year from N/an in Q4 2021.
ProQR Therapeutics' FCF Margin history runs 2 years deep, the most recent figure standing at 2154.72% for Q4 2022.
- In Q4 2022, FCF Margin fell 383255.0% year-over-year to 2154.72%; the TTM figure through Sep 2023 stood at 373.2% (up 108579.0% YoY), while the FY2025 annual figure was 338.31%, down 13830.0% from the prior year.
- FCF Margin came in at 2154.72% for Q4 2022 at ProQR Therapeutics, down from 1857.25% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1677.82% in Q4 2021 to a low of 4085.19% in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -2,154.72% |
| Sep 30, 2022 | -1,857.25% |
| Jun 30, 2022 | -1,571.29% |
| Mar 31, 2022 | -1,789.65% |
| Dec 31, 2021 | 1,677.82% |
| Sep 30, 2021 | -903.90% |
| Jun 30, 2021 | -4,085.19% |